J&J pain combination Ultracet approved
This article was originally published in Pharmaceutical Approvals Monthly
Combo tablet consisting of J&J's Ultram (tramadol) and acetaminophen clears FDA Aug. 15 for short-term (five days or less) management of acute pain. Labeling for the non-narcotic analgesic says the onset of pain relief after Ultracet was faster than with tramadol alone, occurring in less than an hour. Duration of pain relief was longer than with acetaminophen alone, and analgesic effect "was generally comparable to that of…ibuprofen," labeling adds. J&J submitted the NDA Aug. 21, 1999, for chronic as well as acute pain and received an "approvable" letter in June 2000
You may also be interested in...
Biocon has made two key appointments to the management team of Biocon Biologics following a recent change in CEO for the biosimilars business.
The UK's Optibac responds to sustainability and naturals trends with an all-in-one immunity and gut health food supplement especially designed for children.
Legal experts tell the Pink Sheet why India’s plans to abolish the Intellectual Property Appellate Board and shift its powers to courts may be problematic for stakeholders, including those pursuing infringement charges. The transition could mean a significant burden on courts both in terms of capability and capacity, and IPR cases will now conflate into all other pending commercial matters, some experts said, though others cheered the proposed change.